Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
65 hedge funds and large institutions have $27.7M invested in Adaptimmune Therapeutics in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.
21% more capital invested
Capital invested by funds: $22.9M → $27.7M (+$4.84M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
1.51% less ownership
Funds ownership: 45.12% → 43.61% (-1.5%)
3% less funds holding
Funds holding: 67 → 65 (-2)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$547K |
| 2 |
Morgan Stanley
New York
|
+$405K |
| 3 |
EF
Empirical Finance
Havertown,
Pennsylvania
|
+$214K |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
+$29.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$344K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$253K |
| 3 |
JP Morgan Chase
New York
|
-$229K |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$140K |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$129K |
ADAP Hedge Fund Activity: Q2 2025 in Review
65 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2025, worth a combined $27.7M — up 21% from $22.9M a quarter earlier.
Fund positioning in ADAP was balanced in Q2 2025: 11 funds opened new positions, 11 closed out, 10 added to existing stakes and 18 trimmed.
The largest buyer was Two Seas Capital, adding an estimated $547K. The largest seller was Fidelity Investments, cutting an estimated $344K.
- 65 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2025, down from 67 in Q1 2025.
- Funds reported $27.7M of Adaptimmune Therapeutics stock for Q2 2025, up 21% quarter-over-quarter.
- 11 funds opened new Adaptimmune Therapeutics positions in Q2 2025 and 11 closed out, a net change of 0 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2025 was Two Seas Capital, an estimated $547K added.
- The largest Adaptimmune Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $344K sold.
Based on aggregated 13F filings for Q2 2025.